Posted on March 8, 2019
This is a study by CAMH, the leading mental health research hospital in Canada. Learn more about what's involved in participating in a study at CAMH Research Connect.
Research has shown that 25 to 60 per cent of people with schizophrenia use cannabis. For people with schizophrenia, regular cannabis use may be harmful because it has been associated with worsening of symptoms of psychosis.
We are conducting a study to find out if a non-invasive, pain-free brain stimulation treatment, known as repetitive transcranial magnetic stimulation (rTMS), can help people with schizophrenia or schizoaffective disorder quit or reduce their cannabis use and improve their memory.
We are seeking participants who:
- are 18-55 years of age
- use cannabis regularly
- have been diagnosed with schizophrenia or schizoaffective disorder
We will provide 4 weeks of rTMS treatment (5x/week, Monday to Friday) with weekly behavioural support to help people quit or reduce their cannabis use. The rTMS treatments will be provided at CAMH’s Temerty Centre for Therapeutic Brain Intervention. Participants will also complete 3 separate visits at our College St. site to assess their memory/thinking (cognitive abilities).
Participants will receive compensation for their time.
For more information about this research study, please contact us at (416) 535-8501 ext. 34824 or email us at BACDRL@camh.ca.
You can also find our study details in our CAMH study listing.
CAMH REB #: 017/2017